Resverlogix Corp. (RVX) - Net Assets

Latest as of June 2026: CA$-94.12 Million CAD ≈ $-68.08 Million USD

Based on the latest financial reports, Resverlogix Corp. (RVX) has net assets worth CA$-94.12 Million CAD (≈ $-68.08 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$8.24 Million ≈ $5.96 Million USD) and total liabilities (CA$102.36 Million ≈ $74.05 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See RVX equity financing ratio to measure how much of total assets are equity-financed.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$-94.12 Million
% of Total Assets -1141.72%
Annual Growth Rate N/A
5-Year Change N/A
10-Year Change N/A
Growth Volatility 394.84

Resverlogix Corp. - Net Assets Trend (2001–2025)

This chart illustrates how Resverlogix Corp.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Resverlogix Corp. market cap and net worth.

Annual Net Assets for Resverlogix Corp. (2001–2025)

The table below shows the annual net assets of Resverlogix Corp. from 2001 to 2025. Also explore Resverlogix Corp. (RVX) equity growth momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-12-31 CA$-88.80 Million
≈ $-64.24 Million		 -8.64%
2024-12-31 CA$-81.73 Million
≈ $-59.13 Million		 -9.75%
2023-12-31 CA$-74.47 Million
≈ $-53.87 Million		 -25.63%
2022-12-31 CA$-59.28 Million
≈ $-42.88 Million		 +0.98%
2021-12-31 CA$-59.87 Million
≈ $-43.31 Million		 -50.07%
2020-12-31 CA$-39.90 Million
≈ $-28.86 Million		 +37.77%
2019-12-31 CA$-64.11 Million
≈ $-46.38 Million		 +69.14%
2018-12-31 CA$-207.72 Million
≈ $-150.26 Million		 -148.24%
2017-12-31 CA$-83.68 Million
≈ $-60.53 Million		 +17.62%
2016-12-31 CA$-101.57 Million
≈ $-73.47 Million		 -79.99%
2015-12-31 CA$-56.43 Million
≈ $-40.82 Million		 +23.46%
2014-12-31 CA$-73.73 Million
≈ $-53.33 Million		 -16.63%
2013-12-31 CA$-63.22 Million
≈ $-45.73 Million		 -114.26%
2012-12-31 CA$-29.50 Million
≈ $-21.34 Million		 -1176.40%
2011-12-31 CA$2.74 Million
≈ $1.98 Million		 -36.25%
2010-12-31 CA$4.30 Million
≈ $3.11 Million		 -3.67%
2009-12-31 CA$4.46 Million
≈ $3.23 Million		 -61.55%
2008-12-31 CA$11.61 Million
≈ $8.40 Million		 +113.35%
2007-12-31 CA$5.44 Million
≈ $3.94 Million		 +633.01%
2006-12-31 CA$-1.02 Million
≈ $-738.42K		 -113.64%
2005-12-31 CA$7.48 Million
≈ $5.41 Million		 -24.01%
2004-12-31 CA$9.84 Million
≈ $7.12 Million		 +279.07%
2003-12-31 CA$2.60 Million
≈ $1.88 Million		 +175.63%
2002-12-31 CA$942.21K
≈ $681.58K		 +262.89%
2001-12-31 CA$259.64K
≈ $187.82K		 --

Equity Component Analysis

This analysis shows how different components contribute to Resverlogix Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 47691667737.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock CA$334.32 Million %
Other Components CA$53.84 Million %
Total Equity CA$-88.80 Million 100.00%

Resverlogix Corp. Competitors by Market Cap

The table below lists competitors of Resverlogix Corp. ranked by their market capitalization.

Company Market Cap
Pantera Silver Corp
V:PNTR
 $22.43 Million
Alpcot Holding AB Series B
ST:ALPCOT-B
 $22.44 Million
Ulima Nitra PT
JK:UNIQ
 $22.44 Million
Nord Insuretech Group AB
ST:NORDIG
 $22.47 Million
KPX Lifescience.Co.Ltd
KQ:114450
 $22.41 Million
Panca Global Securities Tbk
JK:PEGE
 $22.41 Million
Hamashbir 365 Holdings Ltd
TA:MSBI
 $22.41 Million
Fuji Finance Indonesia Tbk PT
JK:FUJI
 $22.40 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Resverlogix Corp.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from -81,735,000 to -88,800,102, a change of -7,065,102.
  • Net loss of 7,902,965 reduced equity.
  • Other factors increased equity by 837,863.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CA$-7.90 Million -8.9%
Other Changes CA$837.86K +0.94%
Total Change CA$- %

Book Value vs Market Value Analysis

This analysis compares Resverlogix Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2001-12-31 CA$0.08 CA$0.09 x
2002-12-31 CA$0.09 CA$0.09 x
2003-12-31 CA$0.16 CA$0.09 x
2004-12-31 CA$0.48 CA$0.09 x
2005-12-31 CA$0.31 CA$0.09 x
2006-12-31 CA$-0.04 CA$0.09 x
2007-12-31 CA$0.21 CA$0.09 x
2008-12-31 CA$0.39 CA$0.09 x
2009-12-31 CA$0.11 CA$0.09 x
2010-12-31 CA$0.08 CA$0.09 x
2011-12-31 CA$0.04 CA$0.09 x
2012-12-31 CA$-0.40 CA$0.09 x
2013-12-31 CA$-0.80 CA$0.09 x
2014-12-31 CA$-0.87 CA$0.09 x
2015-12-31 CA$-0.56 CA$0.09 x
2016-12-31 CA$-0.96 CA$0.09 x
2017-12-31 CA$-0.61 CA$0.09 x
2018-12-31 CA$-1.02 CA$0.09 x
2019-12-31 CA$-0.29 CA$0.09 x
2020-12-31 CA$-0.17 CA$0.09 x
2021-12-31 CA$-0.25 CA$0.09 x
2022-12-31 CA$-0.23 CA$0.09 x
2023-12-31 CA$-0.27 CA$0.09 x
2024-12-31 CA$-0.30 CA$0.09 x
2025-12-31 CA$-0.31 CA$0.09 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Resverlogix Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-109.04%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2001 -15.09% -663.84% 0.02x 1.14x CA$-65.14K
2002 -54.43% 0.00% 0.00x 1.15x CA$-607.05K
2003 -54.33% -8020.21% 0.01x 1.04x CA$-1.67 Million
2004 -28.82% -1620.79% 0.02x 1.04x CA$-3.82 Million
2005 -85.33% -2620.11% 0.03x 1.08x CA$-7.13 Million
2006 0.00% -5707.10% 0.02x 0.00x CA$-16.45 Million
2007 -516.95% 0.00% 0.00x 3.81x CA$-28.67 Million
2008 -155.95% -13101.81% 0.01x 1.63x CA$-19.26 Million
2009 -615.35% -979685.04% 0.00x 1.89x CA$-27.91 Million
2010 -514.48% -26691.77% 0.01x 1.96x CA$-22.55 Million
2011 -685.22% 0.00% 0.00x 4.51x CA$-19.06 Million
2012 0.00% 0.00% 0.00x 0.00x CA$46.31 Million
2013 0.00% 0.00% 0.00x 0.00x CA$-48.78 Million
2014 0.00% 0.00% 0.00x 0.00x CA$25.70 Million
2015 0.00% 0.00% 0.00x 0.00x CA$-14.07 Million
2016 0.00% 0.00% 0.00x 0.00x CA$-36.05 Million
2017 0.00% 0.00% 0.00x 0.00x CA$-49.94 Million
2018 0.00% 0.00% 0.00x 0.00x CA$20.61 Million
2019 0.00% 0.00% 0.00x 0.00x CA$124.44 Million
2020 0.00% 0.00% 0.00x 0.00x CA$3.99 Million
2021 0.00% 0.00% 0.00x 0.00x CA$-18.78 Million
2022 0.00% 0.00% 0.00x 0.00x CA$2.32 Million
2023 0.00% 0.00% 0.00x 0.00x CA$-9.29 Million
2024 0.00% 0.00% 0.00x 0.00x CA$538.50K
2025 0.00% 0.00% 0.00x 0.00x CA$977.05K

Industry Comparison

This section compares Resverlogix Corp.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $8,436,052
  • Average return on equity (ROE) among peers: -111.56%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Resverlogix Corp. (RVX) CA$-94.12 Million -15.09% N/A $22.41 Million
Appili Therapeutics Inc (APLI) $8.85 Million -61.23% 0.26x $928.58K
Aptose Biosciences Inc (APS) $-2.90 Million 0.00% 0.00x $4.43 Million
Arch Biopartners Inc (ARCH) $73.10K -710.36% 21.41x $45.21 Million
Biomind Labs Inc (BMND) $-1.43 Million 0.00% 0.00x $38.72 Million
Cybin Inc (CYBN) $48.23 Million -98.46% 0.12x $301.37 Million
Eastwood Bio-Medical Canada Inc (EBM) $-840.80K 0.00% 0.00x $89.55 Million
Eupraxia Pharmaceuticals Inc (EPRX) $19.55 Million -117.58% 0.60x $428.67 Million
Devonian Health Group Inc (GSD) $9.38 Million -46.62% 0.78x $17.35 Million
Helix BioPharma Corp. (HBP) $-1.39 Million 0.00% 0.00x $77.35 Million
Hemostemix Inc (HEM) $4.84 Million -81.34% 0.10x $10.23 Million

About Resverlogix Corp.

TO:RVX Canada Biotechnology
Market Cap
$22.41 Million
CA$30.99 Million CAD
Market Cap Rank
#24837 Global
#957 in Canada
Share Price
CA$0.09
Change (1 day)
+0.00%
52-Week Range
CA$0.09 - CA$0.14
All Time High
CA$4.79
Categories
Companies in Canada Biotechnology
About

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID… Read more